Cost-efficiency analysis and expanded treatment access modeling of conversion to rituximab biosimilars from reference rituximab in Jordan

Hala H. Halawaha Al-Zaytoonah University of Jordan, Amman, Jordan

Nimer S. Alkhatiba Al-Zaytoonah University of Jordan, Amman, Jordan;b Center for Health Outcomes and PharmacoEconomic Research, University of Arizon, Tucson, AZ, USA;c PI Pharma Intelligence, Amman, JordanCorrespondence[email protected]

https://orcid.org/0000-0001-5071-9257

Abdulaali R. Almutairid Saudi Food and Drug Authority, Riyadh, Saudi Arabia

https://orcid.org/0000-0002-3141-0606

Mohammad Saleha Al-Zaytoonah University of Jordan, Amman, Jordan;e School of Pharmacy, University of Jordan, Amman, Jordan

https://orcid.org/0000-0003-3298-094X

Shiraz S. Halloushf Applied Science Private University, Amman, Jordan

https://orcid.org/0000-0003-3966-2733

Omar Rashdang School of Pharmacy, Middle East University, Amman, Jordan

https://orcid.org/0000-0002-5192-4823

Lama Masadhh Ministry of Health, Amman, Jordan

Osama H. Abusaraa Al-Zaytoonah University of Jordan, Amman, Jordan

https://orcid.org/0000-0002-0856-5618

Ivo Abrahamb Center for Health Outcomes and PharmacoEconomic Research, University of Arizon, Tucson, AZ, USA;i University of Arizona Cancer Center, University of Arizona, Tucson, AZ, USA;j Matrix45, Tucson, AZ, USA

https://orcid.org/0000-0003-0490-4421

show all

Cost-efficiency analysis and expanded treatment access modeling of conversion to rituximab biosimilars from reference rituximab in Jordan

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Cost-efficiency analysis and expanded treatment access modeling of conversion to rituximab biosimilars from reference rituximab in Jordan

Citations (1)

Read on this site (1)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date